ScholarIQanswers from OpenAlex & ORCID
Arantxa González
ResearcherPublications, citations & collaboration network
Arantxa González is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Arantxa González have?
ScholarIQindexed works
Arantxa González has 334 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Arantxa González have?
ScholarIQcitation count
Arantxa González has 17,254 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Arantxa González?
ScholarIQh-index
Arantxa González has an h-index of 71 in OpenAlex.
What is the i10-index of Arantxa González?
ScholarIQi10-index
Arantxa González has an i10-index of 176 in OpenAlex.
What is the ORCID of Arantxa González?
ScholarIQorcid
The ORCID for Arantxa González is on the source record.
What is the OpenAlex record for Arantxa González?
ScholarIQopenalex
The OpenAlex for Arantxa González is on the source record.
What are the most-cited papers on Arantxa González?
ScholarIQmost cited works
Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Carolyn Y. Ho, Begoña López, Otávio R. Coelho‐Filho, Neal K. Lakdawala, Allison L. Cirino, Petr Jarolı́m, Raymond Y. Kwong, Arantxa González, Steven D. Colan, Jonathan G. Seidman, Javier Dı́ez, Christine E. Seidman
Prevalence of Left Ventricular Diastolic Dysfunction in a General Population
Tatiana Kuznetsova, Lieven Herbots, Begoña López, Yu Jin, Tom Richart, Lutgarde Thijs, Arantxa González, Marie‐Christine Herregods, Robert Fagard, Javier Dı́ez, Jan A. Staessen
T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy
Carolyn Y. Ho, Siddique Abbasi, Tomas G. Neilan, Ravi V. Shah, Yucheng Chen, Bobak Heydari, Allison L. Cirino, Neal K. Lakdawala, E. John Orav, Arantxa González, Begoña López, Javier Dı́ez, Michael Jerosch‐Herold, Raymond Y. Kwong
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
Christoph Maack, Michael Lehrke, Johannes Backs, Frank R. Heinzel, Jean‐Sébastien Hulot, Nikolaus Marx, Walter J. Paulus, Patrick Rossignol, Heinrich Taegtmeyer, Johann Bauersachs, Antoni Bayés‐Genís, Dirk L. Brutsaert, Heiko Bugger, Kieran Clarke, Francesco Cosentino, Gilles W. De Keulenaer, Alessandra Dei, Arantxa González, M Huelsmann, Guido Iaccarino, Ida G. Lunde, Alexander R. Lyon, Piero Pollesello, Graham Rena, Niels P. Riksen, Giuseppe Rosano, Bart Staels, Linda W. van Laake, Christoph Wanner, Dimitrios Farmakis, Gerasimos Filippatos, Frank Ruschitzka, Petar Seferović, Rudolf A. de Boer, Stéphane Heymans
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial
John G.F. Cleland, João Pedro Ferreira, Beatrice Mariottoni, Pierpaolo Pellicori, Joe Cuthbert, Job A.J. Verdonschot, Johannes Petutschnigg, Fozia Ahmed, Franco Cosmi, Hans‐Peter Brunner‐La Rocca, Mamas A. Mamas, Andrew L. Clark, Frank Edelmann, Burkert Pieske, Muhammad Javed Khan, Kenneth McDonald, Philippe Rouet, Jan A. Staessen, Blerim Mujaj, Arantxa González, Javier Dı́ez, Mark R. Hazebroek, Stéphane Heymans, Roberto Latini, Stéphanie Grojean, Anne Pizard, Nicolas Girerd, Patrick Rossignol, Timothy Collier, Faı̈ez Zannad, Dan Atar, Lars Køber, Kenneth Dickstein, Theis Lange